This study will use a retrospective cohort design and will be conducted within routinely collected national healthcare and statutory demographic datasets held by PHS and National Records of Scotland (NRS). As such, there will be no active enrollment of study participants, no direct contact with study participants, no collection of any primary data outside of the standard of care (SOC), and no requirement for informed consent.
This study design was chosen due to several advantages, over other possible designs, including the ability to evaluate incidence of study outcomes in exposed and unexposed infants, ability to follow infants longitudinally to evaluate study outcomes through 12 months of age, and ability to evaluate all-cause outcomes.
Study endpoints, including RSV-associated LRTD hospitalization and RSV-associated hospitalization, among infants born to ABRYSVO-vaccinated mothers (exposed group) will be compared with those among infants born to ABRYSVO-unvaccinated mothers (comparison group) initially from birth through 6 months of age, with later analysis from birth through 12 months as the infants reach this age threshold and their data become available.

Start Date15 May 2026

Sponsor / Collaborator

Pfizer Inc.

NCT07543380

/ RecruitingPhase 3

A PHASE 3, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS CONSIDERED AT HIGH RISK OF SEVERE RSV DISEASE IN JAPAN

The purpose of the study is to learn about the immune response after a RSVpreF vaccination. This study is being conducted in Japan. RSV is a common virus that can cause infections of the lungs and airways.
The study is seeking participants who are:
* 18 to 59 years of age
* adults with health condition(s) that can put them at an increased risk of severe RSV disease
It will also learn about the safety of RSVpreF vaccination. The study lasts about 2 months. Adults need to visit the research site at least 2 times. The participant will receive a phone call 2 months after vaccination for health checks.

Start Date11 May 2026

Sponsor / Collaborator

Pfizer Inc.

NCT07232706

/ RecruitingPhase 3IIT

Prevention of RSV Infection in Infants by Administering Nirsevimab to Infants, With or Without Maternal RSV Vaccination: a Randomised Controlled Trial in France as Part of the Pregnancy and Infant PrEparedness pLatform IN Europe - PIPELINE

RSV (which stands for Respiratory Syncytial Virus) is an infection that causes cold-like symptoms and is most common during winter months. Most people with RSV infection get better by themselves but babies and younger children can become very poorly. About 1 in 15 infants with confirmed RSV within the first 12 months of life will be hospitalised, and a very small proportion will be seriously ill and may die.
Currently there are two different prevention options that can be used to prevent RSV infection in babies. One is a vaccine given to the mother during pregnancy, and the other is a monoclonal antibody given by injection to the baby. Although both prevention options work well on their own and are safe, neither provides 100% protection to the infant. It is not known whether giving both medicines, one to the mother in pregnancy and one to the infant, would provide better protection than giving only one medicine - this is what the PIPELINE-RSV study will look at.
PIPELINE-RSV-France will recruit about 1000 pregnant women in France. A parallel trial, running across Europe (PIPELINE-RSV-International) will recruit about 1500 pregnant women in UK, Switzerland, the Netherlands and Belgium. The protocols will align on key aspects and the data will be analysed together. The study will include two study groups with different prevention options used in each: (1) an injection given to the baby at the beginning of RSV season, or (2) both a vaccine given to the mother in pregnancy and an injection given to the baby at around 4 months of age. Each mother-baby pair will be randomly allocated to group by a computer. The numbers of babies in each of these groups who acquire RSV will be compared. In some countries participating to the International trial, an other study groups may be available : (3) a vaccine given to the mother in pregnancy.
Pregnant women and their babies will be followed until the baby reaches 12 months of age. Information will be collected about medically-important side effects either the mother or the baby had from their medicine(s) and any symptoms of RSV the baby had. Visits with the mother and baby will occur at birth and 12 months later. The mother will complete questionnaires via a Web-based platform to report any non-routine in-person visits, once in pregnancy and after the baby is born twice a month or monthly (more often in the winter), to also report baby's symptoms, to report their trial experience when the baby is 4 and 12 months' old, and to provide their views on vaccination at birth, and when the baby is 4 and 12 months' old. If the baby develops symptoms that might be RSV, their mother or another caregiver will be asked to take a sample using a swab from the baby's nose or mouth, and to send it by post for testing to find out if the baby has RSV.
As well as the main research study, there are also some substudies. A questionnaire will be given to women who consent to take part, to find out their motivations for joining the study and how they prefer to receive information about taking part in studies. A small number of women will be asked to take part in a study to look at how mothers' and babies' immune systems respond to the two different study prevention options , and to investigate different ways of collecting samples from their babies. In addition, researchers will use data from the study to see whether giving both medicines is cost-effective compared with giving just one medicine.

Start Date06 May 2026

Sponsor / Collaborator

Centre Hospitalier Annecy Genevois

100 Clinical Results associated with RSVpreF

100 Translational Medicine associated with RSVpreF

100 Patents (Medical) associated with RSVpreF

543

Literatures (Medical) associated with RSVpreF

31 Dec 2026·Human Vaccines & Immunotherapeutics

Parental acceptability of new RSV preventive therapies for infants: A cross-sectional survey in Canada

Article

Author: Moss, Stephana Julia ; Lee, Janet S W ; Vadlamudi, Nirma Khatri ; Castillo, Eliana ; MacDonald, Shannon E ; Dubé, Ève ; Bolotin, Shelly ; Halperin, Scott A ; MacDonald, Jade ; Fitzpatrick, Tiffany ; Greyson, Devon ; Manca, Terra ; Buchan, Sarah A ; Comeau, Jeannette L ; Papenburg, Jesse ; Parsons Leigh, Jeanna ; Blanchard, Wade ; Halperin, Donna ; Langley, Joanne M ; Brousseau, Nicholas ; Brundin-Mather, Rebecca

Two new RSV immunization products exist for infants: a prenatal vaccine (RSVpreF) and a long-acting monoclonal antibody for infants (nirsevimab). While both showed promise in clinical trials, implementation has varied across jurisdictions. Before rollout in Canada, we conducted an anonymized, online survey with a nationally representative sample of 1,015 expectant and recent birth parents. The primary outcome was product acceptability (disagree, undecided, agree). Odds ratios (ORs) and 95% confidence intervals (CIs) identified factors associated with agreement or indecision versus disagreement. Approximately 49% (n = 499) were expecting; 51% (n = 516) had a baby in the past year. Overall, 72% (n = 727) agreed to receive a product: 61% (n = 624) for RSVpreF and 60% (n = 608) for nirsevimab. RSVpreF agreement was higher among older parents (e.g., OR = 3.64; 95% CI, 1.99-6.67 for age 25-34 versus 18-24 years), those with a university degree (OR = 3.65; 95% CI, 2.01-6.64 versus high school), higher income (OR = 2.31; 95% CI, 1.01-5.28 for ≥$150k versus <$40k), or receipt/intention for Tdap (OR = 3.76; 95% CI, 2.37-5.96 versus no receipt/intention) or influenza (OR = 2.04; 95% CI, 1.29-3.21) vaccines. Agreement was higher among parents of children without a high-risk medical condition compared to those with (OR = 2.32; 95% CI, 1.44-3.72). Similar trends were observed for nirsevimab, with lower agreement also noted among those who self-researched antibodies (OR = 0.51; 95% CI, 0.30-0.88 versus not). As most respondents rated product safety (76%), effectiveness (71%), and disease severity risk (70%) as important in decision-making, providing clear information on these, alongside communications targeted to subgroups with lower agreement, may optimize uptake as programs rollout.

31 Dec 2026·Human Vaccines & Immunotherapeutics

Mucosal immunization with an adenoviral vector expressing a prefusogenic F protein protects the upper and lower respiratory tracts of cotton rats against live respiratory syncytial virus challenge

Article

Author: Wang, Shen ; Wang, Qiyao ; Bao, Jianwei ; Lu, Shuangshuang ; Wu, Ke ; Xu, Long ; Mu, Ting ; Zhang, Ying ; Xie, Liang ; Klein, Michel ; Sun, Bing ; Ma, Tao

Respiratory syncytial virus (RSV) is a major cause of severe respiratory disease in infants, young children, and the elderly. Current licensed prefusogenic F-based RSV vaccines induce systemic immune responses through intramuscular injection. However, mucosal immunization will be required to elicit local sterilizing immunity to prevent virus replication in the nasopharynx and the lungs as well as virus shedding and transmission. Adenovirus vectors are a promising platform to develop RSV vaccines, but further evaluation of mucosal adenovirus-based prefusion F (preF) vaccines is still needed. In this study, we constructed a recombinant chimpanzee adenovirus serotype 68 vector expressing a second-generation disulfide-stabilized (DS2)trimeric preF protein (ChAd68-PreF). In mice, intranasal immunization with ChAd68-PreF induced dose-dependent increase in RSV-specific secretory IgA (sIgA) in the lower respiratory tract, demonstrating its capacity to elict mucosal immunity. Subsequently, in cotton rats, intratracheal instillation of ChAd68-PreF induced high cross-neutralizing antibody titers against RSV A and RSV B. After RSV A2 challenge, ChAd68-PreF vaccinated animals showed no detectable viral replication in the nose nor in the lungs. Moreover, ChAd68-PreF vaccination did not lead to enhanced respiratory disease (ERD) in cotton rats. These results demonstrate that mucosal delivery of ChAd68-PreF confers potent protective immunity against RSV with good safety profile, warranting further clinical development as a mucosa-targeting RSV vaccine for vulnerable populations.

01 Jun 2026·VACCINE

Respiratory syncytial virus (RSV) vaccination program for older Australians reduces health inequalities: a distributional cost-effectiveness analysis

Article

Author: Nazareno, Allen L ; Shih, Sophy T F ; Jan, Stephen ; Wood, James G ; Newall, Anthony T ; Paul, Kishor K ; Torres, Monica ; Gray, Richard T

INTRODUCTION:

Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in individuals aged ≥75 years. Differences in disease burden and vaccine uptake by socio-economic status (SES) are important considerations but are not usually incorporated into traditional cost-effectiveness analyses. We conducted a distributional cost-effectiveness analysis (DCEA) to evaluate RSV vaccination programs for older Australians.

METHODS:

We utilised a static multi-cohort Markov model to simulate age- and SES-specific RSV disease progression in adults aged ≥75 years, comparing no vaccination with the two currently approved RSV vaccines in Australia (Arexvy and Abrysvo). Where available, we used age and SES stratified healthcare utilisation data for RSV as input in the model, with SES represented by the Index of Relative Socio-economic Disadvantage (IRSD). Net health benefits were calculated considering the opportunity costs associated with the vaccination program. We transformed the health distribution from no vaccination and vaccination scenarios and then compared these using a social welfare function.

RESULTS:

We found that all IRSD subgroups benefited from vaccination. Disadvantaged subgroups received larger health benefits, despite relatively lower vaccination uptake, due to higher baseline probability of RSV-related hospitalisation and death. Under the base-case assumptions, including an assumed negotiated price of A$150 per vaccine dose and an opportunity cost threshold of A$50,000 per quality-adjusted life year for all IRSD subgroups, we found an increase in equity and an overall increase in net health benefit. The impact of vaccination on net health and on equity was sensitive to annual RSV incidence, probability of symptomatic RSV episode, vaccine efficacies against RSV hospitalisation, and vaccine price.

CONCLUSION:

RSV vaccination for Australians aged ≥75 years could improve overall population health and reduce existing health inequalities. However, the net health benefits were sensitive to the potential vaccine price to be negotiated by the government in Australia for older adults.

401

News (Medical) associated with RSVpreF

16 Mar 2026

·allsci.com

FDA approves GSK’s RSV vaccine Arexvy for adults aged 18–49

The US FDA has approved an expanded age indication for Arexvy (respiratory syncytial virus vaccine, adjuvanted), GSK’s recombinant protein-based RSV vaccine, extending its use to adults aged 18 to 49 years at increased risk for lower respiratory tract disease caused by RSV. The decision makes Arexvy the third RSV vaccine to receive US FDA approval for at-risk adults under 50, following earlier label expansions for Pfizer’s Abrysvo in October 2024 and Moderna’s mRESVIA in 2025. Arexvy was previously approved in the US for adults aged 60 and older, and for those aged 50 to 59 at increased risk. An estimated 21 million US adults under 50 have at least one risk factor for severe RSV infection, the company said. The expanded indication covers adults aged 18 to 49 with chronic conditions that elevate RSV risk, including cardiopulmonary, kidney, and metabolic diseases such as diabetes and obesity. The vaccine is not approved for use in pregnant individuals. Arexvy contains a recombinant RSV glycoprotein F stabilized in the prefusion conformation (RSVPreF3), combined with GSK’s proprietary AS01E adjuvant system. It is administered as a single dose. The vaccine is now approved for adults 18 and older in the European Economic Area and across more than 60 countries for various adult age groups. The FDA’s decision was supported by data from a Phase IIIb open-label trial (NCT06389487) enrolling 1,458 participants across 52 sites in six countries. The study evaluated the immune response in 426 at-risk adults aged 18 to 49 compared with 429 adults aged 60 and above after a single dose. Primary endpoints were RSV-A and RSV-B neutralization titres at one month post-vaccination. The trial met its non-inferiority endpoints, demonstrating that the immune response in the younger at-risk cohort was non-inferior to that observed in older adults. Vaccine efficacy against RSV-associated lower respiratory tract disease had been established in the earlier Phase III trial (NCT04886596), which enrolled over 26,000 adults aged 60 and above. The safety profile in the expanded population was consistent with the broader Phase III programme, with injection site pain, fatigue, myalgia, headache, and arthralgia the most commonly reported adverse events. The approval places Arexvy alongside two other vaccines now available for younger at-risk adults, forming a competitive landscape that includes protein subunit, mRNA, and bivalent approaches. Pfizer’s Abrysvo, a non-adjuvanted bivalent prefusion F protein vaccine, received its 18-to-59 expansion in October 2024. Moderna’s mRESVIA, the only mRNA-based RSV vaccine, also gained approval for adults 18 to 59 at increased risk in 2025. All three approvals in younger adults relied on immunobridging strategies rather than direct efficacy endpoints in the target population. RSV accounts for approximately 17,000 hospitalisations, 277,000 emergency department visits, and nearly two million outpatient visits annually among US adults aged 18 to 49, with most hospitalisations occurring in those with chronic medical conditions. Prior to these vaccine approvals, no specific prophylactic or therapeutic intervention existed for RSV prevention in this age group. GSK continues to pursue regulatory submissions globally, and the company is conducting additional studies, including a Phase III trial in Chinese adults aged 18 to 59 at increased risk. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Phase 3Drug ApprovalVaccineClinical ResultmRNA

16 Mar 2026

·www.pharmaceutical-technology.com

GSK’s RSV jab secures FDA label expansion to larger adult population

Arexvy will now join Abrysvo and mRESVIA on the high-risk 18-49 market. Credit: MargJohnsonVA / Shutterstock.com. GSK has secured a label expansion for its respiratory syncytial virus (RSV) vaccine, Arexvy, from the US Food and Drug Administration (FDA) – broadening the jab’s commercial reach on American soil. Through this new approval, Arexvy will be available as a preventative measure to non-pregnant adults aged between 18 and 49 years of age, provided they are at increased risk of developing RSV-associated lower respiratory tract disease (LRTD). The FDA based its decision on data from a global Phase IIIb trial (NCT06389487), which confirmed Arexvy’s non-inferiority in immune response across the 18 to 49 age range compared with that seen in patients over 60 in a separate Phase III study (NCT04886596). Arexvy made its market debut in 2023 after becoming the first RSV vaccine to secure regulatory approval in the US – though the shot was originally indicated for the 60+ age demographic only. GSK later secured a label expansion for Arexvy into the 50-59 age category. Since its original approval, Arexvy has encountered competition from both Moderna and Pfizer, as the two pharma companies have both secured regulatory approval for their RSV vaccines, mRESVIA and Abrysvo, across the entire high-risk adult market. According to analysts at GlobalData, parent company of Pharmaceutical Technology , sales of all three vaccines will experience a downturn in the next few years due to shifting attitudes towards vaccines across the US. However, analysts expect Abrysvo to absorb the largest share of the RSV market in 2030 out of the three by bringing in $1bn for Pfizer. GlobalData predicts that Arexvy and mResvia will generate $938m and $502m in sales, respectively, in 2030. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence GSK plans to expand Arexvy’s commercial footprint by submitting further applications for the vaccine to regulators across multiple geographies. US vaccine policy evolves Arexvy’s expanded label comes as the US government looks to alter vaccine policy across the country. In January 2023, the Centers for Disease Control (CDC) updated the routine childhood immunisation schedule , shrinking the recommended list down from 18 vaccines to 11. The RSV vaccine was one of the seven jabs the CDC removed from this schedule. Now, the US health secretary, Robert F Kennedy Jr (RFK Jr), has plans to further reduce this list as he plans to remove seven of the 11 remaining shots on the routine list. This shifting perception can also be observed in the FDA, as the agency’s Center for Biologics Evaluation and Research (CBER) previously declined to review Moderna’s seasonal influenza vaccine, mRNA-1010, due to concerns around the supporting trial’s design. The FDA later pivoted on this take, agreeing to review the drug after Moderna appealed the decision. The FDA’s approval of Arexvy comes soon after FDA commissioner Marty Makary announced that Vinay Prasad would be leaving his post at the helm of CBER for the second time.

Phase 3VaccineDrug ApprovalClinical ResultmRNA

13 Mar 2026

·www.fiercepharma.com

GSK catches up to Pfizer, Moderna with FDA expansion for Arexvy

With an FDA expansion for GSK’s RSV vaccine, Arexvy, for at-risk adults ages 18 to 49, the British company has caught up with Pfizer and Moderna, which scored nods for the age group in 2024 and 2025, respectively. GSK has secured an FDA expansion for its respiratory syncytial virus (RSV) vaccine, Arexvy, for adults ages 18 to 49 who are at increased risk of lower respiratory tract disease caused by the virus. The green light puts GSK on a level playing field with Pfizer and Moderna, which secured endorsements for their RSV shots in 2025 and 2024, respectively. All three of the shots were originally approved for the prevention of RSV in adults 60 and older. In June 2024, GSK gained FDA clearance for at-risk adults age 50 and older, with Pfizer achieving its larger at-risk age expansion four months later.“This age expansion can help address a significant medical need for adults in the United States at higher risk of severe RSV disease due to certain underlying conditions, and help ease pressure on the healthcare system,” Sanjay Gurunathan, M.D., GSK’s vaccines R&D chief, said in a release. Two months ago, Europe signed off on Arexvy’s use for all adults—regardless of their health status—in the same age group.Roughly 17,000 people ages 18 to 49 are hospitalized for RSV in the U.S. each year, GSK said, with most of those affected having chronic medical conditions that place them at risk for severe RSV.The new GSK endorsement comes amid a pressurized vaccine environment in the U.S. In December, the Centers for Disease Control and Prevention (CDC) upended the immunization schedule for children in the U.S., chopping six shots that were previously recommended. Additionally, immunization against RSV—which is the top cause for infant hospitalizations in the U.S., according to the CDC—is now limited to those at high risk and children whose mothers have not been vaccinated.In Arexvy’s first year on the market in 2023, GSK reported worldwide sales of 1.2 billion pounds sterling ($1.49 billion), followed by a decline to 593 million pounds ($757 million) in 2024 and 590 million pounds ($777 million) last year. Meanwhile, sales of Pfizer’s Abrysvo increased from $755 million in 2024 to $1.03 billion last year.

Drug ApprovalVaccine

100 Deals associated with RSVpreF

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pneumonia due to respiratory syncytial virus	European Union	Pfizer Europe MA EEIG	23 Aug 2023
Pneumonia due to respiratory syncytial virus	Iceland	Pfizer Europe MA EEIG	23 Aug 2023
Pneumonia due to respiratory syncytial virus	Liechtenstein	Pfizer Europe MA EEIG	23 Aug 2023
Pneumonia due to respiratory syncytial virus	Norway	Pfizer Europe MA EEIG	23 Aug 2023
Respiratory Syncytial Virus Infections	United States	Pfizer Inc.	31 May 2023
Lower Respiratory Tract Infections	Canada	Pfizer Canada ULC	04 Jan 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Respiratory Tract Infections	Phase 3	United States	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Japan	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Argentina	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Australia	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Brazil	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Canada	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Chile	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Denmark	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Finland	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Gambia	Pfizer Inc.	17 Jun 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06593587 (CTgov)	Phase 3	Respiratory Syncytial Virus Infections	378	Placebo	illtxybrpo = xnhvrkujif qvowfkbtfi (jicnkjiwwp, eipdupqzfw - jggwwrwmyo) View more	-	09 Feb 2026
NCT06473519 (Amélie, CTgov)	Phase 3	Respiratory Syncytial Virus Infections	453	RSVpreF (RSVpreF (With Preservative, MDV))	hmrajsrnou(twkjxffesq) = mrnvkwdiot oqdakxephu (tlnserogay, ugelbtvbrc - oqsmbunymm) View more	-	25 Sep 2025
				RSVpreF (RSVpreF (Without Preservative, SDV))	hmrajsrnou(twkjxffesq) = qghbcxokzy oqdakxephu (tlnserogay, ckcypidkmv - xitfmsffcj) View more
NCT05842967 (MONET, CTgov)	Phase 3	Respiratory Syncytial Virus Infections	885	SSA+RSVpreF (SSA: RSVpreF)	uvhfwkqycd = ufuyjvqrsq mxrjmadpev (fkpuioqbmi, pqcxqxurum - sozagzwdoy) View more	-	08 Aug 2025
				SSA (SSA: Placebo)	uvhfwkqycd = byljyxqkco mxrjmadpev (fkpuioqbmi, rpcfzdsuon - prokmorzmx) View more
NCT04424316 (MATISSE, CTgov)	Phase 3	Respiratory Tract Infections	14,727	RSVpreF (Infant Participants: RSVpreF)	smvkomfgiy = kbqjfqlkjh tcdxpockup (nloxqchwng, dgwstitdpp - kmszujzile) View more	-	11 Feb 2025
				placebo+RSVpreF (Infant Participants: Placebo)	smvkomfgiy = erxkqxcaft tcdxpockup (nloxqchwng, hhpkxmveoz - pnvsbtbldn) View more
NCT05035212 (2021-003693-31, Pubmed \| Clin Infect Dis)	Phase 3	-	-	Bivalent RSV Prefusion F (RSVpreF) Vaccine (RSVpreF 120-µg)	djuemlaojf(fbxsoydsoy) = jsazdfvpvu jhsqsxcacp (jgznbxicsm )	Positive	10 Feb 2025
				Bivalent RSV Prefusion F (RSVpreF) Vaccine (Placebo)	djuemlaojf(fbxsoydsoy) = ldjehfegih jhsqsxcacp (jgznbxicsm )
NCT04424316 (MATISSE, Pubmed \| Obstet Gynecol)	Phase 3	Obstetric Labor, Premature	-	Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine (RSVpreF)	nakvsooxdp(emwxyufvig) = no clinically significant increase in adverse events of special interest, including preterm birth, low birth weight, or neonatal hospitalization, was observed among pregnant people in the overall analysis yirxgwwvbl (adrqlladye ) View more	Positive	01 Feb 2025
				Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine (Placebo)
NCT05842967 (MONeT, PipelineReview) Manual	Phase 3	Respiratory Syncytial Virus Infections	203	ABRYSVO	uthbyahurl(jhxdfnfnts) = ABRYSVO was well-tolerated during the trial, showing a safety profile consistent with findings from other studies of the vaccine. xgjfnepxui (zoqtwxzany ) View more	Positive	12 Aug 2024
NCT04785612 (Phase 2a study, CTgov)	Phase 2	Respiratory Syncytial Virus Infections	70	RSVPreF (RSVPreF)	ufhnvyvauf(meazmifqwk) = jyqunxufbk ultchncblh (rrgozpummv, aqxqvojicm - gvijfqomof) View more	-	07 Aug 2024
				Placebo (Placebo)	ufhnvyvauf(meazmifqwk) = qnujlfxulh ultchncblh (rrgozpummv, wgvcolcnee - imsdjntcun) View more
NCT04424316 (MATISSE, Pubmed)	Phase 3	Respiratory Syncytial Virus Infections	-	RSVpreF vaccine	ayfnfvjuio(zuinbmfxhh) = xdkdwitgqq klvcegmwmt (lnerocuwch ) View more	Positive	08 Jun 2024
				bivalent RSVpreF maternal vaccination (Placebo)	ayfnfvjuio(zuinbmfxhh) = otpffdcrad klvcegmwmt (lnerocuwch ) View more
NCT05842967 (MONeT, Corporate Publications) Manual	Phase 3	Pulmonary Disease, Chronic Obstructive \| Asthma \| Diabetes Mellitus ... View more	-	ABRYSVO	ckfxyhwsfc(mwbnjycktx) = Participants demonstrated RSV-A and RSV-B subgroup neutralizing responses non-inferior to the response seen in the Phase 3 (NCT05035212) RENOIR study of ABRYSVO in more than 34,000 adults aged 60 or older where vaccine efficacy was previously demonstrated. bueofuqbpf (gxkyryrdvo ) Met View more	Positive	09 Apr 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

RSVpreF

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation